Recently CDK4/6 inhibitors have been introduced for the treatment of hormone positive breast cancer resistant to endocrine therapy. Among their side effects, alopecia is often reported being associated to patients’ distress and depressive symptoms.
Case Report
We report the case of a 70-year-old woman affected by breast cancer in treatment with Palbociclib, who developed alopecia.
Management and Outcome: We prescribed a topical solution with cetirizine. Global photography, trichoscopy and trichogram were assessed. All evaluations demonstrated alopecia improvement.
Discussion
Currently, no treatment options for CDK 4/6 inhibitors induced alopecia have been proposed. Herein, we report the use of topical cetirizine.
Group EBCTC, (EBCTCG).
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;
365: 1687–1717.
2.
WilckenNHornbuckleJGhersiD. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer (Review) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. 2011; 2: CD002747. DOI: 10.1002/14651858.CD002747
3.
RoJHuang BartlettCVermaS, et al.Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med2015;
373: 209–219.
4.
LasheenSShohdyKSKassemL, et al.
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther2017;
17: 851–856.
5.
RosmanS. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. 2004; 52: 333–339.
6.
VermaSHuang BartlettCSchnellP, et al.
Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III Study (PALOMA-3). Oncologist2016;
21: 1–11.
7.
LandSRKopecJAYothersG, et al.
Health-related quality of life in axillary node negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B Accepted Manuscript 23. Breast Cancer Res Treat2004;
86: 153–164.
8.
RossiACaterina FortunaMCaroG, et al.
Monitoring chemotherapy-induced alopecia with trichoscopy.J Cosmet Dermatol2019;
18: 575–580.
9.
RossiACampoDFortunaMC, et al.
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia.J Dermatolog Treat2018;
29: 149–151.
10.
GallicchioLCalhounCHelzlsouerKJ.Aromatase inhibitor therapy and hair loss among breast cancer survivors.Breast Cancer Res Treat2013;
142: 435–443.
